Stay updated with breaking news from Prevention Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New Phase 3 trial data finds a single shot of Regeneron's COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said.
Regeneron is pursuing US approval for its Covid-19 monoclonal antibody cocktail as a preventative treatment.
Print this article Regeneron Pharmaceuticals will request federal approval to use its antibody treatment as a preventative measure after researchers found it significantly reduced the risk that healthy trial volunteers exposed to COVID-19 would develop the disease. "These antibodies may be particularly useful in individuals who are not yet vaccinated, and may also have potential in those who are immunosuppressed and may not respond well to vaccines," said Dr. Dan Barouch, co-principal investigator of the Regeneron trial. Researchers determined that the treatment, consisting of four injecti...
Regeneron said a phase three clinical trial of the drug reduced the risk of symptomatic infections in individuals by 81%.
Regeneron to seek U.S. OK for COVID-19 cocktail to be used for prevention By John Miller FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown ZURICH (Reuters) -Regeneron is pursuing U.S. approval for its COVID-19 monoclonal antibody cocktail as a preventative treatment after it helped cut the risk of symptomatic infections in households where someone else is ill, the U.S. drugmaker said on Monday. REGEN-COV, a combination of casirivimab and imdevimab, protected household contacts from exposure to SARS-CoV-2, with...